Net Net Stock Overview

Subscribe

To see hundreds more international net nets, consider subscribing

Overview

Vir Biotechnology Inc
Healthcare
P/NCAV
0.86x
Ticker
VIR
Exchange
NASDAQ
Country
United States
Close
8.12 $
Mkt Cap
1.1B $
EV
847.6M $
NCAV Burn Rate
29.8%
Current Ratio
9.05
Debt/Equity
0.0
EV/REV
9.83x
EV/EBIT
-1.2x
EV/FCF
-1.1x
Dilution
-18.0% p.A
Total Net Income
-229.7M $
Cheapness
99.0%
Vir Biotechnology, Inc. is an immunology company, which is focused on combining cutting-edge technologies to treat and prevent serious infectious diseases and other serious conditions. The Company-s clinical development pipeline consists of product candidates targeting hepatitis delta virus (HDV), hepatitis B virus (HBV), and human immunodeficiency virus (HIV). It also has several preclinical candidates in its pipeline including those targeting influenza A and B, COVID-19, respiratory syncytial virus and human metapneumovirus (RSV and MPV), and human papillomavirus (HPV). The Company-s pipeline includes VIR-1949, VIR-7229, VIR-2981, VIR-8190, and HIV Cure. It also engaged in developing tobevibart, a monoclonal antibody also known as VIR-3434, and Elebsiran, an siRNA also known as VIR-2218, for the treatment and suppression of chronic HDV. Its Elebsiran is an investigational HBV-targeted siRNA that reduces HBsAg, a protein which is required for the HDV viral life cycle.

Profitability

positive values --- Average negative values

Margins

--- Average

Valuation

positive values --- Average negative values

Dilution

--- Average